Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700341 | 0.88 | HTR2C (0.44) | MAPTHTR2CSLC6A4HTR2ARIPK1 | |
| SCHEMBL3700345 | 0.87 | MAPT (0.32) | MAPTALDH1A1NPSR1CNR2 | |
| SCHEMBL4134984 | 0.83 | SLC16A3 (0.36) | MAPTALDH1A1NPSR1HTR2CSLC6A4 | |
| SCHEMBL4120959 | 0.82 | MAPT (0.34) | MAPTALDH1A1NPSR1RIPK1CNR2 | |
| SCHEMBL4131684 | 0.81 | KCNQ3 (0.34) | HTR2CSLC6A4HTR2ARIPK1CNR2 | |
| SCHEMBL3693917 | 0.80 | RIPK1 (0.32) | MAPTALDH1A1NPSR1RIPK1HTT | |
| SCHEMBL4130894 | 0.79 | SLC6A9 (0.36) | MAPTHTR2CSLC6A4SLC6A9HTT | |
| SCHEMBL3700342 | 0.79 | RIPK1 (0.32) | MAPTALDH1A1NPSR1RIPK1CNR2 | |
| SCHEMBL3700717 | 0.79 | KMT2A (0.34) | ALDH1A1HTR2CSLC6A4HTR2ARIPK1 | |
| SCHEMBL2836132 | 0.77 | RIPK1 (0.36) | MAPTALDH1A1NPSR1RIPK1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | MAPT 4258/4885ALDH1A1 1497/4885NPSR1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.